In the unpredictable dance of the stock market, losses aren't defeats; they're the rhythm that teaches us the steps of resilience. Each stumble is a lesson, turning setbacks into a waltz of wisdom, guiding us towards mastery in the market's intricate choreography. #StockMarketWisdom 💡📉💪
Do your patients have questions about NIPS (NIPT)? This brief video helps explain this screening test, what the results may indicate and the importance of follow-up diagnostic testing if clinically indicated. Access resources for you and your patients: https://t.co/gIb8ZRgX2E
Happy first day of #spring! 🌱
As our partners at Hologic shared, it is a great time to reset and reconnect with your #health by scheduling a spring #wellness screening.
@AlertsTtbb And yes I do look at it when I’m not working..just got a new job so my downtime is currently unwinding from the new job and spending quality time with my family as life is short! I do and will look more at Stockcast when I have/make the the time! Thanks for all you do!
@AlertsTtbb May I ask the period of time without engaging you’ve set for auto removal? I work in the corporate world 50+hrs/week and have just started dabbling or as you put lurking on TTBB ($120/month fee) and now Stockcast! I would hope you don’t kick me off while I slowly learn trading!
$POAI Looks like the long term plan you’ve had in the works is starting to be shared with recent appointments! Please share some good quarterly results to quiet the uproar from some investors (I’m sure you have seen)! I still believe in your mission! https://t.co/xHgQZhYpCl
Recently, our SVP Pamela Bush, Ph.D. sat down with @CheckRare to share insight into our Proof of Concept Study—which demonstrated that our PeDAL platform can predict a tumor’s response to a drug with 92% accuracy. Check it out here: https://t.co/eWz0vjxaMG
We're gearing up for the Augmented Intelligence (AI) in Drug Discovery Xchange in San Francisco this Friday. Predictive Oncology SVP Pamela A. Bush, Ph.D., will be on hand to deliver the keynote and network with attendees. Will we see you there? https://t.co/WVhnAKeVHI
Recently, we put our PeDAL platform to the test to prove its value as a tool for AI-driven drug discovery. This hands-on testing revealed exciting results. Get an advanced look at this impressive Proof of Concept report here: https://t.co/twMmcs6HY5
We wish our best to CEO Mel Engle as he announces his retirement, effective Oct. 31. Mel has played an instrumental role in setting up Predictive Oncology for the next stage of growth. This includes several key developments to further strengthen our offerings in drug development.
Please join us for a shareholder earnings call on Friday, August 12, at 12:00 PM ET.
To register and view the webcast, please go to this link: https://t.co/tpFcpj9d52.
For Q&A’s, please register here: https://t.co/TZ1AJlBDXA
$POAI
Predictive Oncology strengthens business and product offerings with the appointment of Chief Scientific Officer, Julia Kirshner, Ph.D., and consolidation and expansion of its research and development arm. $POAI https://t.co/c8KJbZX8VE
We are driven by the impact we have in reducing risk & moving candidates forward confidently with 3D cell culture technology. We're producing more reliable outcomes in drug development and advancing anticancer drug candidates with our zPREDICTA line & Labcorp partnership. $POAI